Reviewing Oncolytics Biotech (NASDAQ:ONCY) & Scinai Immunotherapeutics (NASDAQ:SCNI)

Oncolytics Biotech (NASDAQ:ONCY) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

Oncolytics Biotech has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500.

Earnings & Valuation

This table compares Oncolytics Biotech and Scinai Immunotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76 million	($0.31)	-3.06
Scinai Immunotherapeutics	$1.31 million	0.76	-$8.31 million	($1.06)	-0.24

Scinai Immunotherapeutics has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Oncolytics Biotech and Scinai Immunotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1	0	2	1	2.75
Scinai Immunotherapeutics	1	0	0	0	1.00

Oncolytics Biotech presently has a consensus target price of $8.50, indicating a potential upside of 796.81%. Given Oncolytics Biotech’s stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Scinai Immunotherapeutics.

Profitability

This table compares Oncolytics Biotech and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Scinai Immunotherapeutics	N/A	N/A	N/A

Summary

Scinai Immunotherapeutics beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks.

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.